GHSR and neoplasm: In cancer cachexia mice, KARIs improved food intake and preserved skeletal muscle mass at lower doses (gastrocnemius, 10 mg/kg; p < 0.0001) than synthetic GHSR - 1a agonist (anamorelin, 30 mg/kg) and enhanced functional recovery (rota-rod test, 10 mg/kg; KARI 101 p = 0.045, KARI 201 p = 0.003) without affecting tumour growth.<h4>Conclusions</h4>KARIs are potent, brain-penetrant GHSR-1a agonists with favourable pharmacokinetics compared to anamorelin.